Features | Partner Sites | Information | LinkXpress
Sign In
SEEGENE
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

Superior Single-Cell Library Preparation Technology Now Available for Additional Platforms

By Labmedica International staff writers
Posted on 17 Feb 2014
Image: PicoPLEX DNA-seq kits. Rubicon Genomics’ single-cell library technology now also for Illumina NGS platforms (Photo courtesy of Rubicon Genomics).
Image: PicoPLEX DNA-seq kits. Rubicon Genomics’ single-cell library technology now also for Illumina NGS platforms (Photo courtesy of Rubicon Genomics).
Innovative single-cell DNA library preparation kits can now be used with Illumina sequencing platforms.

Rubicon Genomics (Ann Arbor, MI, USA) now offers its PicoPLEX DNA-seq kits for use with Illumina next-generation sequencing (NGS) platforms. The kits are among Rubicon’s sample-specific library preparation products used in clinical and research testing on NGS, microarray, and quantitative polymerase chain reaction (qPCR) platforms. PicoPLEX’s excellent robustness and reproducibility offer excellent single-cell DNA amplification for microarray and PCR-based preimplantation genetic screening and diagnosis. PicoPLEX DNA-seq now enables clinicians and researchers to access PicoPLEX technology for analyses conducted on Illumina NGS systems.

PicoPLEX DNA-seq kits amplify DNA to yield a highly reproducible NGS-ready library from a single cell with input concentrations of six picograms or less. PicoPLEX DNA-seq employs the same technology currently used by in vitro fertilization (IVF) clinics to detect chromosomal aneuploidies, copy number variations, and single-gene disorders in reproductive cells. It is also used for the genetic characterization of other single-cell samples such as circulating tumor cells. The easy-to-use, three-step process is performed in a single tube or well in less than 3 hours, thereby reducing error and contamination, speeding time to results, and reducing costs.

James Koziarz, PhD, CEO of Rubicon Genomics, commented, “PicoPLEX DNA-seq emphasizes our commitment to increasing the robustness and reproducibility of DNA analyses while also delivering greater speed, efficiency and cost savings. This launch represents another milestone in our ongoing strategy to make Rubicon Genomics’ proprietary library preparation technology available to users of all sequencing platforms.”

Dr. Brian Mariani, chief scientist and scientific director of the Genetics and IVF Institute, helped test the PicoPLEX DNA-seq kits. He commented, “Remarkably, the sequencing data from the PicoPLEX DNA-seq libraries of embryo DNA clearly identified a male balanced translocation that had not been detected by previous microarray and FISH [fluorescence in-situ hybridization] analyses. This is a significant example of how PicoPLEX sequencing data can expose important structural rearrangements missed by other approaches.”

At the 15th annual Advances in Genome Biology and Technology meeting (AGBT 2014; February 12–15, 2014, Marco Island, FL, USA), Rubicon CSO Dr. John Langmore presented studies highlighting PicoPLEX DNA-seq and discussed “Preimplantation genetic screening and diagnostics (PGS/PGD) at low NGS coverage for aneuploidy, CNV, and single-gene disorder detection for in vitro fertilization.”

Related Links:

Rubicon Genomics
PicoPLEX DNA-seq
Advances in Genome Biology and Technology Meeting



PURITAN MEDICAL
ADVANCED INSTRUMENTS
GREINER-BIO-ONE
BioConferenceLive

Channels

Clinical Chemistry

view channel
Image: The ICON 25 hCG point-of-care pregnancy test (Photo courtesy of Beckman Coulter).

Pregnancy Tests Evaluated During Early Gravidity

The predominant hormone human chorionic gonadotropin (hCG) variant in urine, hCG β core fragment (hCGβcf), has been demonstrated to cause false-negative results in qualitative point-of-care (POC) hCG devices.... Read more

Genetic Tests

view channel
Image: The Quant-iT PicoGreen dsDNA Assay Kit (Photo courtesy of Invitrogen).

Blood Test Provides Rapid Method of Detecting Solid Cancers

Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive assessment of cancer burden, but existing detection methods have insufficient sensitivity or patient coverage for broad clinical applicability.... Read more

Pathology

view channel
Image: Micrograph showing prostatic acinar adenocarcinoma, the most common form of prostate cancer (Photo courtesy of Zephron).

New Test Could Accurately Predict Prostate Cancer Recurrence

A test based on genetic signature and tumor oxygen levels, which boost the test’s accuracy, can predict whether a man is at high risk of prostate cancer recurrence. Prostate cancer is the most common... Read more

Industry News

view channel

Roche and Hitachi Renew Alliance in Diagnostics

Roche (Basel, Switzerland) and Hitachi (Tokyo, Japan) have renewed their alliance in the diagnostics business by 10-years for the joint development and manufacture of the next generation of instruments and workflow automation solutions for medical laboratories. The renewed alliance marks a significant milestone towards... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.